Highlights Tofacitinib use did not result in meaningful changes in hematological parameters. Tofacitinib use did not lead to clinically meaningful changes in liver enzymes. ABSTRACT Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebotreated patient cohorts to evaluate the laboratory profiles between baseline and day 7. Methods: We performed post hoc analyses on the following laboratory tests over time during the […]